EYPT (EyePoint) Net Interest Margin (Bank Only) %


EYPT EyePoint Inc EYPT
34 GF Score
Price $14.11
GF Value $0.83
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is EyePoint Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

EYPT
34GF Score
EyePoint Inc EYPT
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is EyePoint (EYPT) Overvalued in 2026?

Based on GuruFocus' analysis, EyePoint stock appears to be overvalued. The current stock price of $14.11 is trading 1600% above its estimated GF Value™ of $0.83. GuruFocus considers EyePoint to be Significantly Overvalued.

Key valuation signals for EYPT:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: $0.83 vs. price of $14.11 (1600% above fair value)
  • GF Score™: 34/100 with 7 warning signs

No single metric tells the full story. See the EYPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

EyePoint Business Description

Other Exchanges PV3B:Germany
Address 480 Pleasant Street, Suite C-400, Watertown, MA, USA, 02472
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
34GF Score

Get the complete analysis for EYPT

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.11
Price
$0.83
GF Value